Vivimed Labs Limited ("Vivimed" or the Company), a niche Specialty Chemicals and Pharmaceuticals company, announced today that it received approval for 2 products from Uzbekistan Government for its PICS & Health Canada approved site, both facilities are situated at Hyderabad
PRODUCT: Bilastin tablets( Brand Name FLUSTIN)- is a second-generation antihistamine (a selective histamine Hi receptor antagonist)
USES: It is used in the treatment of allergic Rhino conjunctivitis and Urticaria (hives).
PRODUCT: Orzole combi
USES: Ofloxacin + Ornidazole is used in the treatment of bacterial & parasitic infections. It is used to treat gastrointestinal infections such as acute diarrhoea or dysentery, gynaecological infections, lung infections and urinary infections.
Commenting on the Approval, Ramesh Krishnamurthy, CEO of Vivimed Labs Ltd said, "We are very excited to receive approval to Vivimed's own products. Vivimed strategy is to increase its share of Branded products in CIS Markets. Vivimed shall be launching these products in 2021. Our purpose is to offer innovative & top quality formulations at affordable prices. This approval is testimony to Vivimed's growth strategy".
Shares of VIVIMED LABS LTD. was last trading in BSE at Rs.17.95 as compared to the previous close of Rs. 17.3. The total number of shares traded during the day was 113551 in over 385 trades.
The stock hit an intraday high of Rs. 18.6 and intraday low of 17.4. The net turnover during the day was Rs. 2046152.